Strategies for organic nanoparticles delivering CRISPR/Cas9 for cancer therapy: Challenges and breakthroughs

Tianqi Zhang; Jing Ding; Qianyu Lv; Mengxin Zhao; Yiran Liu; Qi Wang; Youqi Chen; Haoran Zhao; Hui Ren; Wei Jiang; Ling Zhang; Baofeng Guo

Materials & Design (Aug 2024)

Strategies for organic nanoparticles delivering CRISPR/Cas9 for cancer therapy: Challenges and breakthroughs

Tianqi Zhang,
Jing Ding,
Qianyu Lv,
Mengxin Zhao,
Yiran Liu,
Qi Wang,
Youqi Chen,
Haoran Zhao,
Hui Ren,
Wei Jiang,
Ling Zhang,
Baofeng Guo

Affiliations

Tianqi Zhang: Department of Surgery, China-Japan Union Hospital, Jilin University, Changchun 130033, China
Jing Ding: Department of Pediatrics, Peking University People's Hospital, Beijing 100044, P.R. China
Qianyu Lv: Department of Surgery, China-Japan Union Hospital, Jilin University, Changchun 130033, China
Mengxin Zhao: Department of Surgery, China-Japan Union Hospital, Jilin University, Changchun 130033, China
Yiran Liu: Department of Surgery, China-Japan Union Hospital, Jilin University, Changchun 130033, China
Qi Wang: Key Laboratory of Pathobiology, Ministry of Education, and Department of Biomedical Science, College of Basic Medical Sciences, Jilin University, Changchun 130021, China
Youqi Chen: Department of Surgery, China-Japan Union Hospital, Jilin University, Changchun 130033, China
Haoran Zhao: Department of Surgery, China-Japan Union Hospital, Jilin University, Changchun 130033, China
Hui Ren: Department of Surgery, China-Japan Union Hospital, Jilin University, Changchun 130033, China; Corresponding authors.
Wei Jiang: Academy of Medical Sciences, Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou, Henan, China; Corresponding authors.
Ling Zhang: Key Laboratory of Pathobiology, Ministry of Education, and Department of Biomedical Science, College of Basic Medical Sciences, Jilin University, Changchun 130021, China; Corresponding authors.
Baofeng Guo: Department of Surgery, China-Japan Union Hospital, Jilin University, Changchun 130033, China; Corresponding authors.

Journal volume & issue: Vol. 244
p. 113097

Abstract

Read online

The recent years have witnessed the rapid advancement of clustered regularly interspaced short palindromic repeats/associated protein 9 (CRISPR/Cas9)-mediated gene editing in cancer therapy. The success of cancer gene therapy relies heavily on the development of safe and effective delivery vectors. We focus on organic nanocarriers because of their flexible customizability, which permits them to accomplish excellent delivery efficiency and performance. In this review, the pharmacokinetic behavior of CRISPR/Cas9 nanocarriers serves as a guide to outline the strategies for improving the bioavailability of nanocarriers through physical, chemical, and biological means. Furthermore, the potential of organic nanocarriers for simultaneous delivery of therapeutic agents and gene editing tools is highlighted. Finally, we discuss future directions for the development of cancer therapeutic nanosystems, paving the way for the construction of effective CRISPR/Cas9 delivery systems.

Published in Materials & Design

ISSN: 0264-1275 (Print); 1873-4197 (Online)
Publisher: Elsevier
Country of publisher: United Kingdom
LCC subjects: Technology: Electrical engineering. Electronics. Nuclear engineering: Materials of engineering and construction. Mechanics of materials
Website: https://www.journals.elsevier.com/materials-and-design

About the journal

Abstract

Keywords